Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 199 in MUC17-positive solid tumors
NCT04117958Phase 1Terminated
- Sponsor
- Amgen
- Start
- Jan 2020
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, open-label trial of amg 199 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, colorectal cancer (CRC) and 1 more (2 arms), sponsored by Amgen. Primary endpoints: Dose-limiting toxicities at 3 years, Treatment-emergent adverse events at 3 years and 4 more. Started Jan 2020; status: terminated.
02
Drugs
amg 199
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomacolorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04117958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04117958.